ABT-418

ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects,^{[1][2][3][4][5]} and has been researched for treatment of both Alzheimer's disease^[6] and ADHD.^[7][8][9] It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α₄β₂, α₇/5-HT₃, and α₂β₂ nicotinic acetylcholine receptors but not α3β4 receptors^[10][11][12] ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.^[13]

ABT-418

Identifiers
IUPAC name 3-Methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
CAS Number	147402-53-7 N
PubChem CID	119380
ChemSpider	106627 Y
UNII	B9I6MZL7BW
ChEMBL	ChEMBL274525 Y
CompTox Dashboard (EPA)	DTXSID10163711
Chemical and physical data
Formula	C9H14N2O
Molar mass	166.224 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=NOC(=C1)[C@@H]2CCCN2C
InChI InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1 Y Key:ILLGYRJAYAAAEW-QMMMGPOBSA-N Y
NY (what is this?)  (verify)

See also

• Epiboxidine
• Anabaseine